Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro.

Serfaty L.

Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S53-60. doi: 10.1016/S2210-7401(12)70022-0.

PMID:
23141895
2.

Ursodeoxycholic acid and chemoprevention of colorectal cancer.

Serfaty L, Bissonnette M, Poupon R.

Gastroenterol Clin Biol. 2010 Oct;34(10):516-22. doi: 10.1016/j.gcb.2010.05.005. Epub 2010 Jul 6. Review.

3.

Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons.

Carey EJ, Lindor KD.

Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S61-4. doi: 10.1016/S2210-7401(12)70023-2.

PMID:
23141896
4.

Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development.

Wali RK, Stoiber D, Nguyen L, Hart J, Sitrin MD, Brasitus T, Bissonnette M.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1316-21.

5.

Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.

Khare S, Mustafi R, Cerda S, Yuan W, Jagadeeswaran S, Dougherty U, Tretiakova M, Samarel A, Cohen G, Wang J, Moore C, Wali R, Holgren C, Joseph L, Fichera A, Li YC, Bissonnette M.

Nutr Cancer. 2008;60(3):389-400. doi: 10.1080/01635580701883003.

PMID:
18444174
7.

Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers.

van Gorkom BA, van der Meer R, Boersma-van Ek W, Termont DS, de Vries EG, Kleibeuker JH.

Scand J Gastroenterol. 2002 Aug;37(8):965-71.

PMID:
12229974
8.

Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.

Thompson PA, Wertheim BC, Roe DJ, Ashbeck EL, Jacobs ET, Lance P, Martínez ME, Alberts DS.

Cancer Prev Res (Phila). 2009 Dec;2(12):1023-30. doi: 10.1158/1940-6207.CAPR-09-0234. Epub 2009 Dec 1.

9.

Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid.

Loddenkemper C, Keller S, Hanski ML, Cao M, Jahreis G, Stein H, Zeitz M, Hanski C.

Int J Cancer. 2006 Jun 1;118(11):2750-7.

10.

Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.

Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P; Phoenix and Tucson Gastroenterologist Networks.

J Natl Cancer Inst. 2005 Jun 1;97(11):846-53.

11.

Treatment of NASH with ursodeoxycholic acid: pro.

Ratziu V.

Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S41-5. doi: 10.1016/S2210-7401(12)70020-7. Review.

PMID:
23141893
12.

Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.

Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, Poupon RE, Poupon R.

Hepatology. 2003 Jul;38(1):203-9.

PMID:
12830003
13.

Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.

Sjöqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Löfberg R.

Anticancer Res. 2004 Sep-Oct;24(5B):3121-7.

14.

Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis.

Singh S, Khanna S, Pardi DS, Loftus EV Jr, Talwalkar JA.

Inflamm Bowel Dis. 2013 Jul;19(8):1631-8. doi: 10.1097/MIB.0b013e318286fa61. Review.

PMID:
23665966
15.

Chemoprevention of colorectal cancer: a role for ursodeoxycholic acid, folate and hormone replacement treatment?

Solimando R, Bazzoli F, Ricciardiello L.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):555-68. doi: 10.1016/j.bpg.2011.09.004. Review.

PMID:
22122771
16.

Does ursodeoxycholic acid change the proliferation of the colorectal mucosa?. A randomized, placebo-controlled study.

Ochsenkühn T, Marsteller I, Hay U, Diebold J, Paumgartner G, Göke B, Sackmann M.

Digestion. 2003;68(4):209-16. Epub 2003 Dec 30.

PMID:
14707397
17.

Chemoprevention of colorectal cancer.

Das D, Arber N, Jankowski JA.

Digestion. 2007;76(1):51-67. Epub 2007 Oct 19. Review.

PMID:
17947819
18.

Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.

Hess LM, Krutzsch MF, Guillen J, Chow HH, Einspahr J, Batta AK, Salen G, Reid ME, Earnest DL, Alberts DS.

Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):861-7.

19.

Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells.

Lim SC, Duong HQ, Choi JE, Lee TB, Kang JH, Oh SH, Han SI.

Carcinogenesis. 2011 May;32(5):723-31. doi: 10.1093/carcin/bgr038. Epub 2011 Feb 28.

20.

Ursodeoxycholic acid and in vitro vasoactivity of hydrophobic bile acids.

Bomzon A, Ljubuncic P.

Dig Dis Sci. 2001 Sep;46(9):2017-24.

PMID:
11575458
Items per page

Supplemental Content

Write to the Help Desk